Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan

Brian Orelli, PhD, The Motley Fool
·2-min read
Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan

Novavax (NASDAQ: NVAX) is teaming up with Japanese drug maker Takeda Pharmaceutical (NYSE: TAK) to sell Novavax's coronavirus vaccine, NVX-CoV2373, as a prevention for COVID-19 in Japan. Takeda will be responsible for manufacturing the protein part of the vaccine and will get some help from Japan's Ministry of Health, Labour and Welfare. The agency has pledged to help fund the manufacturing technology transfer, establishment of infrastructure, and scale-up of manufacturing for the vaccine.